
Novavax (NVAX) Stock Forecast & Price Target
Novavax (NVAX) Analyst Ratings
Bulls say
Novavax is a biotechnology company that has a promising vaccine technology with potential broad application for human infectious diseases and has recently received approval and authorization from the FDA and EC for their COVID-19 vaccine, Nuvaxovid. The company's partnerships and in-house early-stage R&D efforts add value to their pipeline, and positive tolerability data and potential market share for their COVID-19 vaccine could drive financial growth in the future. Risks to consider include potential competition, regulatory uncertainties, and market fluctuations, but the overall outlook for Novavax is positive.
Bears say
Novavax is heavily reliant on its adjuvant technology, Matrix-M, which is still relatively untested and requires further partnerships and clinical trials to establish its efficacy and safety. Additionally, competition in the COVID vaccine market and potential for limited access to booster shots for people without risk factors could limit Novavax's revenue potential.
This aggregate rating is based on analysts' research of Novavax and is not a guaranteed prediction by Public.com or investment advice.
Novavax (NVAX) Analyst Forecast & Price Prediction
Start investing in Novavax (NVAX)
Order type
Buy in
Order amount
Est. shares
0 shares